Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Johnson & Johnson commits $990M to land Protagonist’s oral Crohn’s drug
Johnson & Johnson commits $990M to land Protagonist’s oral Crohn’s drug
Johnson & Johnson commits $990M to land Protagonist’s oral Crohn’s drug
Submitted by
admin
on May 30, 2017 - 6:20pm
Source:
Fierce Biotech
News Tags:
JNJ
Protagonist Therapeutics
M&A
Crohn's Disease
PTG-200
Headline:
Johnson & Johnson commits $990M to land Protagonist’s oral Crohn’s drug
Do Not Allow Advertisers to Use My Personal information
